The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.
Breast cancer
CD56
Chromogranin
Neuroendocrine differentiation
Synpatophysin
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
03
02
2020
accepted:
06
05
2020
pubmed:
31
5
2020
medline:
22
6
2021
entrez:
31
5
2020
Statut:
ppublish
Résumé
The latest World Health Organization (WHO) classification categorized invasive breast carcinomas (IBCs) with neuroendocrine (NE) differentiations into neuroendocrine neoplasms (including well-differentiated neuroendocrine tumor [NET] and poorly differentiated neuroendocrine carcinoma [NEC]) and IBC no special type with NE features (IBC-NST-NE). However, little is documented of the clinical significance of this classification; also the precise thresholds and choices of NE markers were variable. In the current study, a large cohort of patients with IBC with NE differentiation were morphologically classified based on the WHO criteria and the clinical relevance of expression of different NE markers (synaptophysin [SYN], chromogranin [CG], and CD56) was evaluated. Among 1,372 IBCs, 52 NET (3.8%) and 172 IBC-NST-NE (12.5%) were identified. Compared with the IBC-no NE cases, NET and IBC-NST-NE were similarly associated with positive estrogen receptor (ER) expression and lower grade (p < .001). For patient outcome, IBC-NST-NE, but not NET, demonstrated significantly worse survival than the IBC-no NE cases. Based on high (≥50%) and low (<50%) expression for each NE marker, independent poor disease-free survival for SYN
Identifiants
pubmed: 32472950
doi: 10.1634/theoncologist.2020-0081
pmc: PMC7485343
doi:
Substances chimiques
Biomarkers, Tumor
0
Chromogranin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1318-e1329Informations de copyright
© AlphaMed Press 2020.
Références
Oncologist. 2016 Jan;21(1):28-32
pubmed: 26659223
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Endocr Pathol. 2003 Winter;14(4):293-301
pubmed: 14739487
BMC Cancer. 2017 Jan 24;17(1):72
pubmed: 28118820
Pathol Int. 2011 Jan;61(1):49-51
pubmed: 21166944
BMC Cancer. 2014 Mar 04;14:147
pubmed: 24589259
Breast. 2004 Aug;13(4):329-33
pubmed: 15325669
Biomed Res Int. 2014;2014:408459
pubmed: 24701575
Cancer. 2010 Oct 1;116(19):4463-73
pubmed: 20572042
Oncotarget. 2016 Jan 12;7(2):1464-76
pubmed: 26621833
Semin Diagn Pathol. 2010 Feb;27(1):69-76
pubmed: 20306832
Mod Pathol. 2018 Dec;31(12):1770-1786
pubmed: 30140036
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
Histopathology. 2016 Feb;68(3):422-32
pubmed: 26114478
N Engl J Med. 2011 Feb 10;364(6):514-23
pubmed: 21306238
J Pathol. 2017 Feb;241(3):405-419
pubmed: 27925203
Histopathology. 2014 Apr;64(5):647-59
pubmed: 24117859
Hum Pathol. 2003 Oct;34(10):1001-8
pubmed: 14608533
Ann Surg Oncol. 2014 Sep;21(9):2928-33
pubmed: 24743910
Mod Pathol. 2018 Jan;31(1):68-82
pubmed: 28884749
Eur Radiol. 2003 Apr;13(4):788-93
pubmed: 12664118
Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):97-103
pubmed: 25679062
Histopathology. 1991 Nov;19(5):403-10
pubmed: 1757079
Int J Surg. 2008;6 Suppl 1:S113-5
pubmed: 19167937
Histopathology. 2002 Mar;40(3):215-22
pubmed: 11895486
Ultrastruct Pathol. 1990 Jul-Aug;14(4):321-34
pubmed: 2200185